Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Sané F[au]:

miRNAs in enterovirus infection. Engelmann I et al. Crit Rev Microbiol. (2018)

Resistance of Enteric Viruses on Fomites. Alidjinou EK et al. Intervirology. (2018)

Fluoxetine can inhibit coxsackievirus-B4 E2 in vitro and in vivo. Benkahla MA et al. Antiviral Res. (2018)

Search results

Items: 1 to 50 of 59

1.

Impact of coxsackievirus-B4E2 combined with a single low dose of streptozotocin on pancreas of outbred mice: investigation of viral load, pathology and inflammation.

Benkahla MA, Sane F, Bertin A, Vreulx AC, Elmastour F, Jaidane H, Desailloud R, Hober D.

Sci Rep. 2019 Jul 12;9(1):10080. doi: 10.1038/s41598-019-46227-3.

2.

Coxsackievirus-B4 Infection of Human Primary Pancreatic Ductal Cell Cultures Results in Impairment of Differentiation into Insulin-Producing Cells.

Bertin A, Sane F, Gmyr V, Lobert D, Dechaumes A, Kerr-Conte J, Pattou F, Hober D.

Viruses. 2019 Jul 2;11(7). pii: E597. doi: 10.3390/v11070597.

3.

Pancreatic beta cells persistently infected with coxsackievirus B4 are targets of NK cell-mediated cytolytic activity.

Nekoua MP, Bertin A, Sane F, Alidjinou EK, Lobert D, Trauet J, Hober C, Engelmann I, Moutairou K, Yessoufou A, Hober D.

Cell Mol Life Sci. 2020 Jan;77(1):179-194. doi: 10.1007/s00018-019-03168-4. Epub 2019 Jun 6.

PMID:
31172216
4.

Emergence of Fluoxetine-Resistant Variants during Treatment of Human Pancreatic Cell Cultures Persistently Infected with Coxsackievirus B4.

Alidjinou EK, Bertin A, Sane F, Caloone D, Engelmann I, Hober D.

Viruses. 2019 May 28;11(6). pii: E486. doi: 10.3390/v11060486.

5.

Aqueous extracts of Syzygium brazzavillense can inhibit the infection with coxsackievirus B4 in vitro.

Badia-Boungou F, Sane F, Alidjinou EK, Hennebelle T, Roumy V, Ngakegni-Limbili AC, Nguimbi E, Moukassa D, Abena AA, Hober D.

J Med Virol. 2019 Jul;91(7):1210-1216. doi: 10.1002/jmv.25436. Epub 2019 Mar 3.

PMID:
30788849
6.

Diabetes progression and alterations in gut bacterial translocation: prevention by diet supplementation with human milk in NOD mice.

Sane F, Scuotto A, Pierrat V, Kacet N, Hober D, Romond MB.

J Nutr Biochem. 2018 Dec;62:108-122. doi: 10.1016/j.jnutbio.2018.08.017. Epub 2018 Oct 4.

PMID:
30292969
7.

Fluoxetine can inhibit coxsackievirus-B4 E2 in vitro and in vivo.

Benkahla MA, Alidjinou EK, Sane F, Desailloud R, Hober D.

Antiviral Res. 2018 Nov;159:130-133. doi: 10.1016/j.antiviral.2018.10.002. Epub 2018 Oct 2.

PMID:
30290197
8.

Serum-derived IgG from coxsackievirus A6-infected patients can enhance the infection of peripheral blood mononuclear cells with coxsackievirus A6.

Aswathyraj S, Sane F, Raghu C, Sabeena S, Alidjinou EK, Arunkumar G, Hober D.

Microb Pathog. 2018 Dec;125:7-11. doi: 10.1016/j.micpath.2018.08.064. Epub 2018 Sep 4.

PMID:
30193952
9.

miRNAs in enterovirus infection.

Engelmann I, Alidjinou EK, Bertin A, Sane F, Hober D.

Crit Rev Microbiol. 2018 Nov;44(6):701-714. doi: 10.1080/1040841X.2018.1499608. Epub 2018 Aug 14. Review.

PMID:
30106324
10.

Coxsackievirus-B4E2 can infect monocytes and macrophages in vitro and in vivo.

Benkahla MA, Elmastour F, Sane F, Vreulx AC, Engelmann I, Desailloud R, Jaidane H, Alidjinou EK, Hober D.

Virology. 2018 Sep;522:271-280. doi: 10.1016/j.virol.2018.06.010. Epub 2018 Jul 26.

11.

Salivary anti-coxsackievirus-B4 neutralizing activity and pattern of immune parameters in patients with type 1 diabetes: a pilot study.

Nekoua MP, Yessoufou A, Alidjinou EK, Badia-Boungou F, Moutairou K, Sane F, Hober D.

Acta Diabetol. 2018 Aug;55(8):827-834. doi: 10.1007/s00592-018-1158-3. Epub 2018 May 17.

PMID:
29774468
12.

Inhibition of coxsackievirus B4 by Lactobacillus plantarum.

Arena MP, Elmastour F, Sane F, Drider D, Fiocco D, Spano G, Hober D.

Microbiol Res. 2018 May;210:59-64. doi: 10.1016/j.micres.2018.03.008. Epub 2018 Mar 19.

13.

Antiviral Properties of Chemical Inhibitors of Cellular Anti-Apoptotic Bcl-2 Proteins.

Bulanova D, Ianevski A, Bugai A, Akimov Y, Kuivanen S, Paavilainen H, Kakkola L, Nandania J, Turunen L, Ohman T, Ala-Hongisto H, Pesonen HM, Kuisma MS, Honkimaa A, Walton EL, Oksenych V, Lorey MB, Guschin D, Shim J, Kim J, Than TT, Chang SY, Hukkanen V, Kulesskiy E, Marjomaki VS, Julkunen I, Nyman TA, Matikainen S, Saarela JS, Sane F, Hober D, Gabriel G, De Brabander JK, Martikainen M, Windisch MP, Min JY, Bruzzone R, Aittokallio T, Vähä-Koskela M, Vapalahti O, Pulk A, Velagapudi V, Kainov DE.

Viruses. 2017 Sep 25;9(10). pii: E271. doi: 10.3390/v9100271.

14.

Enteroviruses in blood of patients with type 1 diabetes detected by integrated cell culture and reverse transcription quantitative real-time PCR.

Alidjinou EK, Sane F, Lefevre C, Baras A, Moumna I, Engelmann I, Vantyghem MC, Hober D.

Acta Diabetol. 2017 Nov;54(11):1025-1029. doi: 10.1007/s00592-017-1041-7. Epub 2017 Aug 31.

PMID:
28861621
15.

Evaluation of Contamination Risks with Coxsackievirus B4 E2 in Swiss Albino Mice Stools.

Aguech-Oueslati L, Jaidane H, Sane F, Jrad-Battikh N, Hamed SB, Hober D, Gharbi J.

Curr Microbiol. 2018 Jan;75(1):32-39. doi: 10.1007/s00284-017-1347-2. Epub 2017 Aug 30.

PMID:
28856411
16.

Marker of coxsackievirus-B4 infection in saliva of patients with type 1 diabetes.

Badia-Boungou F, Sane F, Alidjinou EK, Ternois M, Opoko PA, Haddad J, Stukens C, Lefevre C, Gueorguieva I, Hamze M, Ismail M, Weill J, Monabéka HG, Bouenizabila E, Moukassa D, Abena AA, Hober D.

Diabetes Metab Res Rev. 2017 Oct;33(7). doi: 10.1002/dmrr.2916. Epub 2017 Aug 30.

PMID:
28719027
17.

Resistance of Enteric Viruses on Fomites.

Alidjinou EK, Sane F, Firquet S, Lobert PE, Hober D.

Intervirology. 2018;61(5):205-213. doi: 10.1159/000448807. Epub 2017 Jun 15. Review.

18.

Persistent coxsackievirus B4 infection induces microRNA dysregulation in human pancreatic cells.

Engelmann I, Alidjinou EK, Bertin A, Bossu J, Villenet C, Figeac M, Sane F, Hober D.

Cell Mol Life Sci. 2017 Oct;74(20):3851-3861. doi: 10.1007/s00018-017-2567-0. Epub 2017 Jun 10.

PMID:
28601984
19.

Bifidobacteria-derived lipoproteins inhibit infection with coxsackievirus B4 in vitro.

El Kfoury KA, Romond MB, Scuotto A, Alidjinou EK, Dabboussi F, Hamze M, Engelmann I, Sane F, Hober D.

Int J Antimicrob Agents. 2017 Aug;50(2):177-185. doi: 10.1016/j.ijantimicag.2017.03.010. Epub 2017 Jun 17.

PMID:
28595938
20.

Persistence of Coxsackievirus B4 in pancreatic ductal-like cells results in cellular and viral changes.

Alidjinou EK, Engelmann I, Bossu J, Villenet C, Figeac M, Romond MB, Sané F, Hober D.

Virulence. 2017 Oct 3;8(7):1229-1244. doi: 10.1080/21505594.2017.1284735. Epub 2017 Jan 23.

21.

Anti-coxsackievirus B4 (CV-B4) enhancing activity of serum associated with increased viral load and pathology in mice reinfected with CV-B4.

Elmastour F, Jaïdane H, Benkahla M, Aguech-Oueslati L, Sane F, Halouani A, Engelmann I, Bertin A, Mokni M, Gharbi J, Aouni M, Alidjinou EK, Hober D.

Virulence. 2017 Aug 18;8(6):908-923. doi: 10.1080/21505594.2016.1252018. Epub 2016 Oct 28.

22.

In-utero coxsackievirus B4 infection of the mouse thymus.

Jaïdane H, Halouani A, Jmii H, Elmastour F, Abdelkefi S, Bodart G, Michaux H, Chakroun T, Sane F, Mokni M, Geenen V, Hober D, Aouni M.

Clin Exp Immunol. 2017 Mar;187(3):399-407. doi: 10.1111/cei.12893. Epub 2016 Nov 29.

23.

Exposure of Piglets to Enteroviruses Investigated by an Immunoassay Based on the EV-G1 VP4 Peptide.

Benkahla MA, Sane F, Desailloud R, Hober D.

Intervirology. 2016;59(2):69-73. doi: 10.1159/000449058. Epub 2016 Oct 1.

24.

Central nervous system infection following vertical transmission of Coxsackievirus B4 in mice.

Jmii H, Halouani A, Elmastour F, Ifie E, Richardson SJ, Sane F, Mokni M, Aouni M, Hober D, Jaïdane H.

Pathog Dis. 2016 Nov;74(8). pii: ftw096. doi: 10.1093/femspd/ftw096. Epub 2016 Sep 20.

PMID:
27655912
25.

Immunoglobulin G-dependent enhancement of the infection with Coxsackievirus B4 in a murine system.

Elmastour F, Jaidane H, Aguech-Oueslati L, Benkahla MA, Aouni M, Gharbi J, Sane F, Hober D.

Virulence. 2016 Jul 3;7(5):527-35. doi: 10.1080/21505594.2016.1152442. Epub 2016 Mar 30.

26.

High Efficiency of Functional Carbon Nanodots as Entry Inhibitors of Herpes Simplex Virus Type 1.

Barras A, Pagneux Q, Sane F, Wang Q, Boukherroub R, Hober D, Szunerits S.

ACS Appl Mater Interfaces. 2016 Apr 13;8(14):9004-13. doi: 10.1021/acsami.6b01681. Epub 2016 Apr 4.

PMID:
27015417
27.

Coxsackievirus B4 Can Infect Human Peripheral Blood-Derived Macrophages.

Alidjinou EK, Sané F, Trauet J, Copin MC, Hober D.

Viruses. 2015 Nov 24;7(11):6067-79. doi: 10.3390/v7112924.

28.

Antibodies to VP1 of swine pasivirus in humans without evidence of transmission from a pig source.

Arnold F, Hober D, Chaussade H, Dumarest M, Sané F, Nowakowsjki M, Rigaud E, Bellalou J, Desailloud R, Coursaget P, Eloit M.

J Clin Virol. 2015 Aug;69:36-9. doi: 10.1016/j.jcv.2015.05.026. Epub 2015 Jun 3.

PMID:
26209375
29.

New Insights into the Understanding of Hepatitis C Virus Entry and Cell-to-Cell Transmission by Using the Ionophore Monensin A.

Fénéant L, Potel J, François C, Sané F, Douam F, Belouzard S, Calland N, Vausselin T, Rouillé Y, Descamps V, Baumert TF, Duverlie G, Lavillette D, Hober D, Dubuisson J, Wychowski C, Cocquerel L.

J Virol. 2015 Aug;89(16):8346-64. doi: 10.1128/JVI.00192-15. Epub 2015 Jun 3.

30.

Survival of Enveloped and Non-Enveloped Viruses on Inanimate Surfaces.

Firquet S, Beaujard S, Lobert PE, Sané F, Caloone D, Izard D, Hober D.

Microbes Environ. 2015;30(2):140-4. doi: 10.1264/jsme2.ME14145. Epub 2015 Apr 3.

31.

Persistent infection of human pancreatic cells with Coxsackievirus B4 is cured by fluoxetine.

Alidjinou EK, Sané F, Bertin A, Caloone D, Hober D.

Antiviral Res. 2015 Apr;116:51-4. doi: 10.1016/j.antiviral.2015.01.010. Epub 2015 Feb 2.

PMID:
25655448
32.

Viruses contained in droplets applied on warmed surface are rapidly inactivated.

Firquet S, Beaujard S, Lobert PE, Sané F, Caloone D, Izard D, Hober D.

Microbes Environ. 2014;29(4):408-12. doi: 10.1264/jsme2.ME14108. Epub 2014 Dec 3.

33.

Enterovirus persistence as a mechanism in the pathogenesis of type 1 diabetes.

Alidjinou EK, Sané F, Engelmann I, Geenen V, Hober D.

Discov Med. 2014 Nov;18(100):273-82. Review.

34.

Higher levels of hepatitis C virus RNA found in blood donors co-infected with HIV as compared to HCV mono-infected donors.

Alidjinou EK, Moukassa D, Ebatetou-Ataboho E, Mahoungou GH, Pambou JP, Sané F, Prevost B, Bocket L, Ibara JR, Hober D.

J Infect Dev Ctries. 2014 Aug 13;8(8):1068-71. doi: 10.3855/jidc.4767.

35.

Detection of hepatitis B virus infection markers in dried plasma spots among patients in Congo-Brazzaville.

Alidjinou EK, Moukassa D, Sané F, Twagirimana Nyenyeli S, Akoko EC, Mountou MV, Bocket L, Ibara JR, Hober D.

Diagn Microbiol Infect Dis. 2014 Mar;78(3):229-31. doi: 10.1016/j.diagmicrobio.2013.09.019. Epub 2013 Nov 26.

PMID:
24342801
36.

Serum-dependent enhancement of coxsackievirus B4-induced production of IFNα, IL-6 and TNFα by peripheral blood mononuclear cells.

Alidjinou EK, Sané F, Engelmann I, Hober D.

J Mol Biol. 2013 Dec 13;425(24):5020-31. doi: 10.1016/j.jmb.2013.10.008. Epub 2013 Oct 11.

PMID:
24120940
37.

Noise intensity-intensity correlations and the fourth cumulant of photo-assisted shot noise.

Forgues JC, Sane FB, Blanchard S, Spietz L, Lupien C, Reulet B.

Sci Rep. 2013 Oct 8;3:2869. doi: 10.1038/srep02869.

38.

Coxsackievirus B4 can infect human pancreas ductal cells and persist in ductal-like cell cultures which results in inhibition of Pdx1 expression and disturbed formation of islet-like cell aggregates.

Sane F, Caloone D, Gmyr V, Engelmann I, Belaich S, Kerr-Conte J, Pattou F, Desailloud R, Hober D.

Cell Mol Life Sci. 2013 Nov;70(21):4169-80. doi: 10.1007/s00018-013-1383-4. Epub 2013 Jun 18.

PMID:
23775130
39.

Synergistic effect between colistin and bacteriocins in controlling Gram-negative pathogens and their potential to reduce antibiotic toxicity in mammalian epithelial cells.

Naghmouchi K, Baah J, Hober D, Jouy E, Rubrecht C, Sané F, Drider D.

Antimicrob Agents Chemother. 2013 Jun;57(6):2719-25. doi: 10.1128/AAC.02328-12. Epub 2013 Apr 9.

40.

Cervical samples dried on filter paper and dried vaginal tampons can be useful to investigate the circulation of high-risk HPV in Congo.

Alidjinou EK, Ebatetou-Ataboho E, Sané F, Moukassa D, Dewilde A, Hober D.

J Clin Virol. 2013 Jun;57(2):161-4. doi: 10.1016/j.jcv.2013.02.010. Epub 2013 Mar 9.

PMID:
23478164
41.

Human milk can neutralize Coxsackievirus B4 in vitro.

Sane F, Alidjinou EK, Kacet N, Moukassa D, Charlet C, Ebatetou-Ataboho E, Ngoulou W, Badia-Boungou F, Romond MB, Hober D.

J Med Virol. 2013 May;85(5):880-7. doi: 10.1002/jmv.23518. Epub 2013 Feb 13.

PMID:
23408519
42.

Antibodies enhance the infection of phorbol-ester-differentiated human monocyte-like cells with coxsackievirus B4.

Goffard A, Alidjinou EK, Sané F, Choteau L, Bouquillon C, Caloone D, Lobert PE, Hober D.

Microbes Infect. 2013 Jan;15(1):18-27. doi: 10.1016/j.micinf.2012.10.005. Epub 2012 Oct 26.

PMID:
23108316
43.

Persistent infection of thymic epithelial cells with coxsackievirus B4 results in decreased expression of type 2 insulin-like growth factor.

Jaïdane H, Caloone D, Lobert PE, Sane F, Dardenne O, Naquet P, Gharbi J, Aouni M, Geenen V, Hober D.

J Virol. 2012 Oct;86(20):11151-62. Epub 2012 Aug 1.

44.

Prolonged viral RNA detection in the central nervous system of one-week-old Swiss albino mice following coxsackievirus B4 and echovirus 9 infection.

El Hiar R, Hober D, Jaidane H, Sané F, M'hadheb-Gharbi MB, Caloone D, Gharbi J, Aouni M.

Intervirology. 2012;55(6):435-41. doi: 10.1159/000335549. Epub 2012 Mar 6.

PMID:
22398876
45.

Immunology in the clinic review series; focus on type 1 diabetes and viruses: role of antibodies enhancing the infection with Coxsackievirus-B in the pathogenesis of type 1 diabetes.

Hober D, Sane F, Jaïdane H, Riedweg K, Goffard A, Desailloud R.

Clin Exp Immunol. 2012 Apr;168(1):47-51. doi: 10.1111/j.1365-2249.2011.04559.x. Review.

46.

Immunology in the clinic review series; focus on type 1 diabetes and viruses: enterovirus, thymus and type 1 diabetes pathogenesis.

Jaïdane H, Sané F, Hiar R, Goffard A, Gharbi J, Geenen V, Hober D.

Clin Exp Immunol. 2012 Apr;168(1):39-46. doi: 10.1111/j.1365-2249.2011.04558.x. Review.

47.

Specificity of the coxsackievirus B4 VP4 capsid protein investigated in silico.

Goffard A, Sané F, Soumillon M, Hober D.

Discov Med. 2011 Aug;12(63):153-8.

48.

Group B coxsackieviruses and autoimmunity: focus on Type 1 diabetes.

Sané F, Moumna I, Hober D.

Expert Rev Clin Immunol. 2011 May;7(3):357-66. doi: 10.1586/eci.11.11. Review.

PMID:
21595602
49.

Enteroviruses and type 1 diabetes.

Hober D, Sane F.

BMJ. 2011 Feb 3;342:c7072. doi: 10.1136/bmj.c7072. No abstract available.

PMID:
21292717
50.

Enteroviral pathogenesis of type 1 diabetes.

Hober D, Sane F.

Discov Med. 2010 Aug;10(51):151-60. Review.

Supplemental Content

Support Center